CD8A and neoplasm: Importantly, we had previously demonstrated that SA-4-1BBL costimulation renders Teff cells refractory to suppression by Treg cells and increases the ratio of CD8+ Teff to Treg cells at the tumor site when used as the adjuvant component of tumor associated antigens (TAAs)-based vaccines [12], [13].